Results 71 to 80 of about 26,046 (277)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Efficiency of phencarol in combination with standard antiarrhythmic drugs in extrasystoles in children

RUDN Journal of Medicine, 2008
The efficiency of multimodality therapy with use standard antiarrhythmic drugs (cordaron and propanorm) in minimum efficient doses and phencarol (1-2 mg/kg) was investigated in 50 children's with extrasistoles, class II-IV by Lown, as compared with ...
O N Soldatova, L A Balykova, L M Makarov, V N Komolyatova, S N Chuprova, O M Soldatov, T I Kornilova   +6 more
doaj  

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments.
Nagomi Kurebayashi, Masami Kodama, Hana Inoue, Masato Konishi, Masami Sugihara, Takashi Murayama, Ryosuke Ishida, Koichiro Ishii, Shuichi Mori, Yukari Endo, Xi Zeng, Yukiko U. Inoue, Takayoshi Inoue, Satoru Noguchi, Hajime Nishio, Eri Nakashima, Norio Suzuki, Noriko Nakaya, Ryushi Sato, Yuya Otori, Ayuna Tsutsumi, Mirei Takahashi, Takayuki Oka, Haruo Ogawa, Kayoko Kanamitsu, Hiroyuki Kusuhara, Utako Yokoyama, Junko Kurokawa, Hiroyuki Kagechika, Takashi Sakurai   +29 more
wiley   +1 more source

Diltiazem N‐oxide, a novel ischaemia‐activated prodrug, prevents ischaemia‐induced ventricular fibrillation without off‐target adverse effects

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ventricular fibrillation (VF) in coronary heart disease accounts for up to 70% of sudden cardiac death. We examined whether diltiazem N‐oxide (DNO) has ischaemia‐selective antiarrhythmic activity. Experimental Approach Randomised and blinded experiments were performed in rat isolated hearts and in anaesthetised rats to ...
Louise M. Hesketh, Gabriel A. Watson, Francesca Mazzacuva, Zoe Hoare, Thomas R. Eykyn, Michael J. Curtis   +5 more
wiley   +1 more source

Response to equine cardiac adverse events during sports

Equine Veterinary Education, EarlyView.
Summary Cardiac adverse events and sudden death are a feared scenario for equine veterinarians, with serious consequences for animal health, riders' safety and the social licence to operate equestrian sports. The response to equine cardiac adverse events (CAEs) during sports is poorly defined.
C. Navas de Solis, J. Keen, A. Decloedt, B. Delvescovo, K. Hopster, K. Mitchell, J. Slack, G. van Loon, G. Van Steenkiste, L. Nath   +9 more
wiley   +1 more source

Prospects for Combination Antiarrhythmic Drug Therapy in Cardiology: Is It Time for a Polypill?

Russian Open Medical Journal
In this article, we discuss the feasibility of combination antiarrhythmic drug therapy in the form of a polypill. In our opinion, this type of treatment is currently limited by various factors discussed in this article. Large-sample studies are needed to
Anatoly O. Rubanenko, Andrey A. Garanin, Anton R. Kiselev   +2 more
doaj   +1 more source

Antiarrhythmic therapy in the treatment of atrial fibrillation: yesterday, today, tomorrow

Кардиоваскулярная терапия и профилактика, 2019
Atrial fibrillation (AF) is the most common heart rhythm disorder encountered in clinical practice. Each year, the number of patients with AF significantly increases.
V. I. Podzolkov, A. I. Tarzimanova
doaj   +1 more source

Antiarrhythmic drug and antithrombotic therapy after catheter ablation between the AF recurrence and SR maintenance groups.

, 2018
Antiarrhythmic drug and antithrombotic therapy after catheter ablation between the AF recurrence and SR maintenance groups.
Dae-In Lee (5537753), Seung-Young Roh (4789593), Jong-Il Choi (2582920), Jinhee Ahn (4529095), Jaemin Shim (3183030), Dong-Hyeok Kim (5314817), Kwang-No Lee (5537750), Young-Hoon Kim (286883)   +7 more
core   +1 more source

Anti‐cancer drugs targeting the NADH‐binding site of VDAC rewire channel electrophysiology and partially suppress cation selectivity

The FEBS Journal, EarlyView.
VA molecules alter VDAC1 gating by increasing anion flow and reducing cation permeability. In cancer cells, which rely on ER‐mitochondria Ca2+ transfer and overexpress VDAC1, this imbalance triggers bioenergetic stress, ROS buildup, and mitochondrial collapse, leading to cell death.
Stefano Conti‐Nibali, Giuseppe Battiato, Salvatore Antonio Maria Cubisino, Cristina Arrigoni, Marco Lolicato, Simona Reina, Vito De Pinto   +6 more
wiley   +1 more source

Catheter Ablation: Evolution and Efficiencies

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT The present review includes a discussion the goals and pitfalls of efficiency in the medical profession, a historical perspective on the evolution of catheter ablation in the field of electrophysiology (EP), and the data regarding the relationship between efficiency and outcomes in the EP lab. Focus on efficacy is critical to maximize resource
Aravind G. Kalluri, Bradley P. Knight
wiley   +1 more source